GlassScriptPhysician profile
Kendall D Jenson
NPI 1881706885
$38,606.47
in general payments reported to CMS, 2019-2025
34 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,362 · 2022: $4,297 · 2023: $8,779 · 2024: $12K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,180 · Honoraria: $1,130 · Travel and Lodging: $879 · Education: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,382.43 |
| Consulting Fee | $11,990.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,180.00 |
| Honoraria | $1,130.00 |
| Travel and Lodging | $879.16 |
| Education | $386.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,888.99 | 2021-2025 | |
| Incyte Corporation | $3,507.49 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $3,282.44 | 2021-2025 | Absorica Ld, Winlevi, Blu-U |
| Leo Pharma INC. | $3,120.01 | 2021-2025 | Adbry, Anzupgo |
| Abbvie INC. | $2,874.97 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,600.37 | 2021-2025 | Siliq, Cabtreo, Jublia |
| E.R. Squibb & Sons, L.L.C. | $2,214.94 | 2022-2025 | Sotyktu |
| Journey Medical Corporation | $2,053.22 | 2022-2025 | |
| Janssen Biotech, INC. | $1,791.74 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Dermavant Sciences, INC. | $1,765.32 | 2023-2024 | Vtama |
| Amgen INC. | $1,491.58 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $1,366.22 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Regeneron Healthcare Solutions, INC. | $1,310.13 | 2021-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $1,259.67 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $965.17 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $622.35 | 2021-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $513.18 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $468.89 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Vyne Pharmaceuticals INC. | $434.95 | 2021 | |
| Genzyme Corporation | $339.63 | 2021-2025 | |
| Botanix Sb INC | $169.39 | 2025 | Sofdra |
| Biofrontera INC. | $92.33 | 2021-2022 | |
| Epi Health, LLC | $90.58 | 2021-2022 | |
| Genentech USA, INC. | $87.98 | 2025 | Xolair |
| Blueprint Medicines Corporation | $67.89 | 2025 | Ayvakit |
| Organon LLC | $52.49 | 2025 | Vtama, Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.42 | 2023 | Spevigo |
| Almirall LLC | $27.98 | 2022-2024 | Seysara |
| Kyowa Kirin, INC. | $23.02 | 2022 | |
| Biocon Biologics INC | $22.51 | 2024 | Hulio |
| Allergan, INC. | $21.21 | 2022 | |
| Fresenius Kabi USA, LLC | $20.22 | 2023 | |
| Boston Scientific Corporation | $17.02 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Jenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.